Youn H Kim
Affiliation: Stanford University
- Review of the treatment of mycosis fungoides and sézary syndrome: a stage-based approachSteven M Horwitz
Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Natl Compr Canc Netw 6:436-42. 2008..Many milder therapies may be repeated several times in the disease course, and maintenance and tapering strategies are common. This article also discusses the emerging role of allogeneic stem cell transplantation...
- Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcomeDenise K Woo
Department of Dermatology, Stanford University, Stanford, CA 94305, USA
Arch Dermatol 145:667-74. 2009....
- Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative ProjectYoun H Kim
Youn H Kim, Mahkam Tavallaee, Uma Sundram, Shufeng Li, Sima Rozati, Seema Nagpal, Michael Krathen, Sunil Reddy, Richard T Hoppe, Annie Nguyen Lin, Wen Kai Weng, Randall Armstrong, and Ranjana H Advani, Stanford University, Stanford, CA Katrin A Salva and Gary S Wood, University of Wisconsin and William S Middleton Memorial Veterans Hospital, Madison, WI and Melissa Pulitzer and Steven M Horwitz, Memorial Sloan Kettering Cancer Center, New York, NY
J Clin Oncol 33:3750-8. 2015..Clinical activity and safety of brentuximab vedotin, a CD30 targeting antibody-drug conjugate, was evaluated in MF and SS. Tissue and blood biomarkers of clinical response were explored...
- Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsinYoun H Kim
Stanford Cancer Center, Stanford, CA, USA
Leuk Lymphoma 54:284-9. 2013..Median time to CMRP was 1.8 months, and median duration of CMRP was 5.6 months. Study results suggest that the clinical benefit of romidepsin may extend beyond objective responses...
- In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 studyYoun H Kim
Department of Dermatology, Stanford University School of Medicine, CA, USA
Blood 119:355-63. 2012..This study is registered at www.clinicaltrials.gov as NCT00226993...
- Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experienceYoun H Kim
Department of Dermatology, Stanford University School of Medicine, 900 Blake Wilbur Dr, No W0069, Stanford, CA 94305, USA
Arch Dermatol 139:165-73. 2003..To evaluate and update the response and survival outcomes and toxic effects in patients treated with topical nitrogen mustard (mechlorethamine hydrochloride) as primary therapy...
- Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphomaYoun H Kim
Department of Dermatology, Multidisciplinary Cutaneous Lymphoma Program, Stanford Cancer Center, Stanford, California 94305, USA
J Am Acad Dermatol 63:975-83. 2010..PF-3512676 (formerly CPG 7909) is a Toll-like receptor 9 agonist that is being investigated for treatment of patients with advanced cancer...
- Management with topical nitrogen mustard in mycosis fungoidesYoun H Kim
Department of Dermatology, Multidisciplinary Cutaneous Lymphoma Group, Stanford University School of Medicine, Stanford, California 94305, USA
Dermatol Ther 16:288-98. 2003..Topical NM is used safely in pediatric patients and there is no evidence of any clinically significant systemic absorption of topically applied NM...
- Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphomaYoun H Kim
Multidisciplinary Cutaneous Lymphoma Program, Stanford Comprehensive Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
Blood 109:4655-62. 2007..The treatment was well tolerated with no dose-related toxicity other than the targeted depletion of peripheral T cells. A pivotal study has been initiated based on these findings...
- TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of ResearYoun H Kim
Department of Dermatology, Stanford Comprehensive Cancer Center, Stanford, CA 94305, USA
Blood 110:479-84. 2007..Due to the clinical and pathologic heterogeneity of the cutaneous lymphomas, the currently proposed TNM system is meant to be primarily an anatomic documentation of disease extent and not to be used as a prognostic guide...
- Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphomaWen Kai Weng
Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
Sci Transl Med 5:214ra171. 2013..We have thus demonstrated the utility of TCRB HTS to assess MRD with increased sensitivity and specificity compared to other current methodologies, and to monitor response to therapy in this MF/SS patient population. ..
- Clinicopathologic features and treatment outcomes in Woringer-Kolopp diseaseJuliette Lee
Department of Dermatology, Stanford University School of Medicine, Stanford, California 94305, USA
J Am Acad Dermatol 59:706-12. 2008..Our observations confirm that Woringer-Kolopp disease carries an excellent prognosis, and support that the most effective and appropriate treatment for recalcitrant or severe Woringer-Kolopp disease is localized radiation therapy...
- Combined use of PCR-based TCRG and TCRB clonality tests on paraffin-embedded skin tissue in the differential diagnosis of mycosis fungoides and inflammatory dermatosesBing Zhang
Department of Pathology, L235, Stanford University Medical Center, Stanford, CA 94305, USA
J Mol Diagn 12:320-7. 2010..Combined use of the two tests in patients with intermediate pretest probabilities as proposed in the algorithm could improve test utility...
- In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II studyJoshua D Brody
269 Campus Dr CCSR rm 1105, Stanford, CA 94305, USA
J Clin Oncol 28:4324-32. 2010..In a preclinical lymphoma model, intratumoral injection of a Toll-like receptor 9 (TLR9) agonist induced systemic antitumor immunity and cured large, disseminated tumors...
- Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progressionYoun H Kim
Department of Dermatology, Stanford University School of Medicine, Stanford, CA 94305, USA
Arch Dermatol 139:857-66. 2003..To study and update the clinical characteristics and long-term outcome of our patients with mycosis fungoides (MF) and Sézary syndrome (SS), and to identify important clinical factors predictive of survival and disease progression...
- A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disordersMadeleine Duvic
Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4003, USA
Clin Cancer Res 15:6217-24. 2009....
- Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphomaChristiane Querfeld
Department of Dermatology, Northwestern University, Chicago, IL 60611, USA
Leuk Lymphoma 52:1474-80. 2011..Enzastaurin was well tolerated with mostly grade 1-2 adverse events, mainly diarrhea and fatigue. There were two adverse event-related drug discontinuations with one possibly treatment-related...
- Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximabAnjali V Morales
Multidisciplinary Cutaneous Lymphoma Program, Stanford Comprehensive Cancer Center, Stanford, California 94305, USA
J Am Acad Dermatol 59:953-7. 2008..Rituximab is a chimeric monoclonal IgG1 antibody directed against the CD20 antigen of B cells. Clinical efficacy of systemic rituximab in CBCL has yet to be established...
- CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphomaHoward L Liu
Department of Dermatology, Stanford University, 900 Blake Wilbur Drive, Stanford, CA 94305, USA
J Am Acad Dermatol 49:1049-58. 2003..Prior studies have shown CD30+CLPDs have an excellent prognosis...
- Clonal identity and differences in primary cutaneous B-cell lymphoma occurring at different sites or time points in the same patientMika Fujiwara
Department of Pathology, Stanford University Medical Center, Stanford, CA 94305 5324, USA
Am J Dermatopathol 35:11-8. 2013..Although the study is small and the results need to be confirmed in a larger study, these findings suggest that a subset of PCBCL at different sites may represent different primary tumors rather than occurrence of a single disease...
- Intravascular ALK-negative anaplastic large cell lymphoma with localized cutaneous involvement and an indolent clinical course: toward recognition of a distinct clinicopathologic entityRyan A Metcalf
Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA
Am J Surg Pathol 37:617-23. 2013....
- The frequency of dual TCR-PCR clonality in granulomatous disordersSalma Dabiri
Department of Pathology, Stanford University Medical Center, Stanford, CA 94305, USA
J Cutan Pathol 38:704-9. 2011..The frequency of T-cell clonality in association with granulomatous dermatitides has not yet been established...
- Evaluation of B-cell clonality using the BIOMED-2 PCR method effectively distinguishes cutaneous B-cell lymphoma from benign lymphoid infiltratesAnjali V Morales
Department of Dermatology, Stanford University Medical Center, Stanford, CA 94305, USA
Am J Dermatopathol 30:425-30. 2008..This study forms the basis for further investigating the role of Ig clonality in distinguishing CBCL from benign lymphoid infiltrates that may pose a challenge in morphologic diagnosis...
- Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK)Madeleine Duvic
Department of Dermatology, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
Clin Lymphoma 2:222-8. 2002..Heavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL, skin appearance, and pruritus severity...
- Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphomaSteven M Horwitz
Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
Blood 119:4115-22. 2012..The most common grade 3 adverse event (AE) was mucositis (17%); the only grade 4 AE was leukopenia (3%). Pralatrexate 15 mg/m(2)/wk for 3/4 weeks shows high activity with acceptable toxicity in patients with relapsed/refractory CTCL...
- Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndromeChristiane Querfeld
Department of Medicine Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY
Blood 123:1159-66. 2014..In conclusion, lenalidomide monotherapy demonstrated activity in refractory cutaneous T-cell lymphomas, along with acceptable toxicity. This trial was registered at www.clinicaltrials.gov as #NCT00466921. ..
- Transcriptome sequencing in Sezary syndrome identifies Sezary cell and mycosis fungoides-associated lncRNAs and novel transcriptsCAROLYN S LEE
Programs in Epithelial Biology, Department of Dermatology, Stanford University, CA, USA
Blood 120:3288-97. 2012..Our findings characterize the SS transcriptome and support recent reports that implicate lncRNA dysregulation in human malignancies...
- The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoidesDaniel Navi
Department of Dermatology, Stanford University, Stanford, CA, USA
Arch Dermatol 147:561-7. 2011....
- Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohortsKathie P Huang
Department of Dermatology, Stanford University School of Medicine, Stanford, CA 94305, USA
Arch Dermatol 143:45-50. 2007..To assess risks for developing second malignancies in patients with mycosis fungoides or Sézary syndrome...
- Cytologic evaluation of lymphadenopathy associated with mycosis fungoides and Sezary syndrome: role of immunophenotypic and molecular ancillary studiesReetesh K Pai
Department of Pathology, Stanford University, Stanford, California 94305, USA
Cancer 114:323-32. 2008..With fine-needle aspiration biopsy, material can be collected for ancillary diagnostic studies and for morphologic evaluation...
- Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomographyEunice Y Tsai
Department of Dermatology, Stanford University School of Medicine, Stanford, Calif, USA
Arch Dermatol 142:577-84. 2006..To evaluate the usefulness of integrated positron emission tomography and computed tomography (PET/CT) in staging mycosis fungoides (MF) and Sézary syndrome and to correlate PET/CT data with histopathologic diagnosis of lymph nodes (LNs)...
- Lymph node involvement by mycosis fungoides and Sézary syndrome mimicking angioimmunoblastic T-cell lymphomaRobert E LeBlanc
Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305
Hum Pathol 46:1382-9. 2015....
- The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patientsMichael J Kelly-Sell
Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA
Am J Hematol 87:354-60. 2012..05). These findings raise concern that HDACis suppress immune function in CTCL patients and they support the concurrent use of multiple immune stimulatory agents to preserve the host immune response...
- Useful Parameters for Distinguishing Subcutaneous Panniculitis-like T-Cell Lymphoma From Lupus Erythematosus PanniculitisRobert E LeBlanc
Departments of Pathology Dermatology, Stanford University School of Medicine, Stanford, CA
Am J Surg Pathol 40:745-54. 2016..We confirm that SPTCL and LEP can show significant histologic overlap, suggest a role for high-throughput sequencing in confirming neoplastic clones, and introduce the concept of SPTCL "Ki-67 hotspots" in evolving disease. ..
- Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populationsNeha Mehta
Department of Medicine, New York Presbyterian Weil Cornell Medical Center, 1275 York Avenue, New York, NY 10021, USA
Clin Lymphoma Myeloma Leuk 12:20-5. 2012..There is no standard treatment, although chemotherapy and hematopoietic stem cell transplantation are commonly used. We describe results using bexarotene for children and adults with these disorders...
- Clinical and pathological features of posttransplantation lymphoproliferative disorders presenting with skin involvement in 4 patientsDavid P Beynet
Department of Dermatology, Stanford University School of Medicine, Stanford, CA 94305, USA
Arch Dermatol 140:1140-6. 2004..Although extranodal involvement in PTLD is common, cutaneous presentation is rare, with only 19 cases reported previously...
- Cutaneous involvement by angioimmunoblastic T-cell lymphoma: a unique histologic presentation, mimicking an infectious etiologyAnu G Jayaraman
Department of Pathology, Stanford University Medical Center, Stanford, California 94305 5324, USA
J Cutan Pathol 33:6-11. 2006....
- Subcutaneous panniculitis-like T-cell lymphoma: Pediatric case series demonstrating heterogeneous presentation and option for watchful waitingEmily E Johnston
Department of Pediatrics, Stanford University School of Medicine, Stanford, California
Pediatr Blood Cancer 62:2025-8. 2015..Three patients had spontaneous, durable remissions without treatment, whereas the one patient with disease progression was treated successfully. Watchful waiting may thus be appropriate for initial management of children...
- T-cell clonality analysis in biopsy specimens from two different skin sites shows high specificity in the diagnosis of patients with suggested mycosis fungoidesStacy E Thurber
Department of Pathology, Stanford University, Stanford, California 94035, USA
J Am Acad Dermatol 57:782-90. 2007....
- Gene expression profiles of cutaneous B cell lymphomaMonique N Storz
Department of Pathology, Division of Medical Oncology, Stanford University Medical Center, Stanford, California 94305, USA
J Invest Dermatol 120:865-70. 2003....
- Neurotropic Gamma-Delta T-Cell Lymphoma With CD30-Positive Lymphoid InfiltratesBryan Gammon
Departments of Pathology, and Dermatology, Stanford Medicine, Stanford, CA
Am J Dermatopathol 38:e133-6. 2016..In this article, the authors describe an extraordinary case of a CD30-positive PCGD-TCL to expand the histopathological spectrum of CD30-positive and gamma-delta-positive lymphoproliferative disorders. ..
- Non-Hodgkin's lymphomas, version 1.2013Andrew D Zelenetz
Memorial Sloan Kettering Cancer Center, USA
J Natl Compr Canc Netw 11:257-72; quiz 273. 2013....
- Experimental treatment strategies in primary cutaneous T-cell lymphomasSima Rozati
Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA
Curr Opin Oncol 28:166-71. 2016..Cutaneous T-cell lymphoma (CTCL) comprises a heterogeneous group of malignancies derived from skin-homing or resident T cells. Effective treatments are limited, thus new therapies are in development to address the unmet medical need...
- Primary Cutaneous Gamma-Delta T-Cell Lymphoproliferative Disorder in a 3-Year-Old BoyChristopher W M Soon
Departments of Pathology, Pediatric Hematology and Oncology, and Dermatology, Stanford University Medical Center, Stanford, CA
Am J Dermatopathol 37:567-9. 2015..We hope to add to the recognition that PCGD-TCLs demonstrate a wide clinical spectrum of disease with relatively indolent presentations in some cases. ..
- Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic ModelJulia J Scarisbrick
Julia J Scarisbrick and Felicity Evison, University Hospital Birmingham, Birmingham Richard Cowan, The Christie Hospital, Manchester Stephen Morris and Sean J Whittaker, St Thomas Hospital, London, United Kingdom H Miles Prince and Robert Twigger, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia Maarten H Vermeer and Rein Willemze, Leiden University Medical Centre, Leiden, the Netherlands Pietro Quaglino, Paolo Fava, and Milena Maule, University of Turin Torino, Turin Emilio Berti, Francesco Onida, and Laura Corti, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca Granda Ospedale Maggiore Policlinico, University of Milano Bicocca, Milan Nicola Pimpinelli and Vieri Grandi, University of Florence, Florence Alessandro Pileri and Annalisa Patrizi, University of Bologna, Bologna, Italy Steven Horwitz and Christiane Querfeld, Memorial Sloan Kettering Cancer Center, New York, NY Pierluigi Porcu, Henry Wong, and Kelly Tyler, Ohio State University, Columbus, OH Gary S Wood, University of Wisconsin, Madison, California 92697
J Clin Oncol 33:3766-73. 2015..Published prognostic studies in MF/SS have been single-center trials. Because of the rarity of MF/SS, only a large collaboration would power a study to identify independent prognostic markers...
- Occult Dermal Lymphatic Involvement Is Frequent in Primary Cutaneous Anaplastic Large Cell LymphomaDita Gratzinger
Departments of Pathology, Radiation Oncology, and Dermatology, Stanford University School of Medicine, Stanford, CA
Am J Dermatopathol 37:767-70. 2015....
- European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomasNancy J Senff
Department of Dermatology, Leiden University Medical Center, Leiden, The Netherlands
Blood 112:1600-9. 2008..They may therefore contribute to uniform staging and treatment and form the basis for future clinical trials in patients with a CBCL...
- Interstitial mycosis fungoides, a variant of mycosis fungoides resembling granuloma annulare and inflammatory morpheaLyndon D Su
Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA
J Cutan Pathol 29:135-41. 2002..Interstitial mycosis fungoides (IMF) is a rare variant of mycosis fungoides that resembles the interstitial form of granuloma annulare and inflammatory morphea. IMF has received little attention in the literature...
- Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphomaElise A Olsen
Duke University, Durham, NC, USA
J Clin Oncol 25:3109-15. 2007....
- Prognosis, clinical outcomes and quality of life issues in cutaneous T-cell lymphomaMarie France Demierre
Department of Dermatology and Medicine, Boston University School of Medicine, 720 Harrison Avenue, DOB 801A, Boston, MA 02118, USA
Hematol Oncol Clin North Am 17:1485-507. 2003..Nevertheless, physicians who are caring for patients who have advanced MF/SS should acknowledge the spiritual dimension as an integral component of the dying process...
- Non-Hodgkin's lymphomasAndrew D Zelenetz
J Natl Compr Canc Netw 6:356-421. 2008
- Expression of HGAL in primary cutaneous large B-cell lymphomas: evidence for germinal center derivation of primary cutaneous follicular lymphomaXiuyan Xie
Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH 44195, USA
Mod Pathol 21:653-9. 2008..Characterizing PCLBCLs with markers of B-cell maturation stage is a useful framework for studying, classifying, and clinically stratifying these lymphomas...
- Bexarotene gel: a Food and Drug Administration-approved skin-directed therapy for early-stage cutaneous T-cell lymphomaHoward L Liu
Arch Dermatol 138:398-9. 2002